3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
NET
1
Endocrine
1
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
5760
Lung Neoplasms
3725
Small Cell Lung Carcinoma
1021
Breast Neoplasms
668
Neoplasms
615
Colorectal Neoplasms
562
Melanoma
479
Ovarian Neoplasms
435
Neoplasm Metastasis
432
Pancreatic Neoplasms
387
Stomach Neoplasms
332
Carcinoma, Renal Cell
312
Adenocarcinoma of Lung
309
Squamous Cell Carcinoma of Head and Neck
306
Head and Neck Neoplasms
295
Prostatic Neoplasms
285
Mesothelioma, Malignant
281
Esophageal Neoplasms
266
Mesothelioma
244
Colonic Neoplasms
226
Brain Neoplasms
217
Urinary Bladder Neoplasms
212
Triple Negative Breast Neoplasms
212
Uterine Cervical Neoplasms
209
Endometrial Neoplasms
175
Sarcoma
172
Carcinoma, Hepatocellular
159
NSCLC
136
Carcinoma
128
Kidney Neoplasms
127
Interventions
Vinorelbine
1
Gemcitabine
1
Drug Therapy
1
Cisplatin
1
Cilengitide
1
Cetuximab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Metatropic dwarfism
×
Thoracic
×
Clear all
NCT00842712
2017-01-13
CERTO
Merck KGaA, Darmstadt, Germany
Phase 2
Completed
232 enrolled
17 charts